1. Kovesdy CP (2011) (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12(1):7–11. https://doi.org/10.1016/j.kisu.2021.11.003
2. Overview: Dapagliflozin for treating chronic kidney disease: guidance. NICE. https://www.nice.org.uk/guidance/ta775. Accessed 18 February
3. Overview: Chronic kidney disease: assessment and management: guidance. NICE. https://www.nice.org.uk/guidance/ng203. Accessed 18 February
4. FDA approves treatment for chronic kidney disease. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease. Accessed 18 February 2023
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720